![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/en/news-release/2024/07/09/2910763/0/en/Voting-Rights-and-Shares-Capital-of-the-Company.html
https://www.globenewswire.com/news-release/2024/06/12/2897888/0/en/NANOBIOTIX-to-Host-Virtual-KOL-Event-Discussing-Potential-of-NBTXR3-Combined-With-Immunotherapy-in-Head-and-Neck-Cancer-and-Beyond-on-June-18-2024.html
https://www.globenewswire.com/news-release/2024/06/11/2897173/0/en/Voting-Rights-and-Shares-Capital-of-the-Company.html
https://www.globenewswire.com/news-release/2024/06/02/2891853/0/en/Nanobiotix-Announces-New-Data-Showing-Disease-Control-and-Tumor-Response-in-Patients-Treated-With-RT-Activated-NBTXR3-Followed-By-anti-PD-1-For-2l-R-M-HNSCC-Na%C3%AFve-or-Resistant-to-P.html
https://www.globenewswire.com/news-release/2024/05/28/2889429/0/en/NANOBIOTIX-Announces-Presentation-of-new-Data-From-Phase-1-Immunotherapy-Program-at-the-2024-Annual-Meeting-of-the-American-Society-for-Clinical-Oncology-Followed-by-an-Investor-Co.html
https://www.globenewswire.com/news-release/2024/05/23/2887652/0/en/NANOBIOTIX-to-Present-at-the-Jefferies-Global-Healthcare-Conference.html
https://www.globenewswire.com/news-release/2024/05/22/2886183/0/en/NANOBIOTIX-Provides-First-Quarter-2024-Operational-and-Financial-Update.html
https://www.globenewswire.com/news-release/2024/05/21/2886036/0/en/Nanobiotix-Announces-Progress-in-Global-NBTXR3-Development-Collaboration-Highlighting-Robust-Pipeline-and-Pathway-to-Long-Term-Growth.html
https://www.globenewswire.com/news-release/2024/05/16/2883881/0/en/Voting-Rights-and-Shares-Capital-of-the-Company.html